🇺🇸 FDA
Patent

US 10947302

Compositions targeting 3-repeat tau for the treatment of neurodegenerative disorders, and methods for making and using them

granted A61KA61K2039/505A61K9/0019

Quick answer

US patent 10947302 (Compositions targeting 3-repeat tau for the treatment of neurodegenerative disorders, and methods for making and using them) held by The Regents of the University of California expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K2039/505, A61K9/0019, A61K9/1075, A61K9/127